Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Novo Nordisk's (NVO) stock was up more than 12% in pre-market trading Friday on news the company's latest weight loss product ...
Hosted on MSN1mon
Novo Nordisk new obesity therapy CagriSema outperforms semaglutide in Phase 3 trial
While Novo (NVO) said it was encouraged by the results, its shares crashed ~23% in European trading. Another Phase 3 trial called REDEFINE 2 for adults with type 2 diabetes and either obesity or ...
pharmaphorum5d
Novo Nordisk once-weekly insulin clears first phase 3 test
but Novo Nordisk is trying to change that. The Danish drugmaker has reported the first phase 3 results with its new basal insulin product – insulin icodec – which backs up earlier data ...